23 May 2013
Keywords: aventis, immunogen, sign, deal, develop, anticancer, therapies
Article | 04 August 2003
Aventis and ImmunoGen have entered into an agreement to develop novel antibody-based cancer therapies. Under the deal, Aventis will obtain ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 August 2003
28 July 2003
© 2013 thepharmaletter.com